Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Efficacy, and Tolerability of Tezacaftor/Ivacaftor (TEZ/IVA) in an Orkambi-experienced Population

Administered By

Awarded By

Contributors

Start/End

  • February 13, 2018 - June 27, 2019